Uterine carcinomas: Chemotherapy for primary and recurrent tumors

Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches

Volumn , Issue , 2004, Pages 519-527

  Downs, Levi S ^a   Boente, Matthew P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646914550     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Estimated new cancer cases and deaths by gender, US, 2002. Cancer Facts & Figures.
2. Boente MP, Yordan EL, McIntosh D, Grendys E, Orandi Y, Davies S, Beck D, Graham JE, Miller A, Marshall R, Dolan T, Kirschner C, Bergan S, Reddy S, Wilbanks G. Prognostic factors and long-term survival in endometrial adenocarcinoma. Gynecol Oncol 1993; 51:316–322.
3. Boente MP, Orandi Y, Yordan EL, Graham JE, Kirschner C, Miller A, Reddy S, Wilbanks G. Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement. Ann Surg Oncol 1995; 2(2):138–144.
4. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63:21–27.
5. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12(7):1408–1414.
6. Thigpen T, Blessing J, Homesley H, et al. Phase III trial of doxorubicin +/ cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstr]. Proc Am Soc Clin Oncol 1993; 12:261.
7. Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978; 62(1):159–161.
8. Calero F, Asins-Codoner E, Jimeno J, Rodriguez Escudero F, Mendana J, Iglesias J, Matia F, Armas A, Diaz-Castellanos R, Garzon J. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 1991; 27(7):864–866.
9. Edmonson JH, Krook JE, Hilton JF, Malkasian GC, Everson LK, Jefferies JA, Mailliard JA. Randomized phase II studies of Cisplatin and a combination of cyclophosphamide–doxorubicin–cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 1987; 28(1):20–24.
10. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 33:68–70.
11. Deppe G, Cohen CJ, Bruckner HW. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiamine platinum (II) after intensive prior therapy. Gynecol Oncol 1980; 10:51–54.
12. Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 1984; 7:253–256.
13. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22(5):67–75.
14. Burke TW, Munkarah A, Kavanagh JJ, Morris M, Levenback C, Tornos C, Gershenson DM. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993; 51:397–400.
15. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62:278–281.
16. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7:861– 863.
17. Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 1996; 19(3):290–291.
18. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994; 21(1):107–113.
19. Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1993; 16(1):18–21.
20. Seski JC, Edwards CL, Copeland LJ. Hexamethylmelamine as first line therapy in the treatment of advanced or recurrent carcinoma of the endometrium, a phase II trial of the Gynecologic Oncology Group. Obstet Gynecol 1993; 16:18–21.
21. Thigpen JT, Blessing JA, Ball H, Hanjani P, Manetta A, Homesley H. Hexamethylmel-amine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 1988; 31:435–438.
22. Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, Mailliard JA. Randomized phase II studies of cisplatin and a combination of cyclophosphamide– doxorubicin–cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 1987; 28:20–24.
23. Turbow MM, Ballon SC, Sikic BI, Koretz MM. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep 1985; 69(5):465–467.
24. Hancock KC, Freedman RS, Edwards CL, Rutledge FN. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 1986; 70(6):789–791.
25. Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, Edwards CL. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1991; 40:264–267.
26. Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, Mikuta JJ. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1991; 41:113–116.
27. Deppe G, Malviya VK, Malone JM, Christensen CW, Saunders D. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol 1994; XV(4):263–266.
28. Trope´ C, Johnsson JE, Simonsen E, Christiansen H, Cavallin-Sta˚ hl E, Horva´ th G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 1984; 149(4):379–381.
29. Seltzer V, Vogl SE, Kaplan BH. Adriamycin and cis-diaminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol Oncol 1984; 19:308–313.
30. Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC, Galindo A Jr. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep 1985; 69(5):539–542.
31. Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin–cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16(6):494– 496.
32. Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000; 78:52–57.
33. Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19(20):4048–4053.
34. Price FV, Edwards RP, Kelley JL, Kunschner AJ, Hart LA. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 1997; 24(5 suppl 15):S15-78–S15-82.
35. Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP III. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19(4):1021–1029.
36. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C. Cisplatin-, epirubicin-and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 1997; 8:969–972.
37. Boente MP, Schilder RJ, Babb JS, Campbell FJ, Langer CJ, Bergman CA, Goldstein LJ, Ozols RF. Abstract of carboplatin (Carbo) and paclitaxel (PAC) in advanced and recurrent papillary serous uterine carcinoma (UPSC). International Gynecologic Cancer Society, Rome, Italy.
38. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961; 264(5):216–222.
39. Sall S, DiSaia P, Morrow CP, Mortel R, Prem K, Thigpen T, Creasman W. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am J Obstet Gynecol 1979; 135(5):647–650.
40. Thigpen T, Blessing J, DiSaia P. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels—the Gynecologic Oncology Group experience. In: Baulier E, Iacobelli S, McGuire W, eds. Endocrinology and Malignancy. New York: Parthenon Publishers, 1986:446–454.
41. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17:1736–1744.
42. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19:364–367.
43. Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 2001; 24(1):43–46.
44. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anas-trozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78:212–216.
45. Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Franssen E, Roche K. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997; 64:126–129.
46. Lhomme´ C, Vennin P, Callet N, Lesimple T, Achard JL, Chauvergne J, Luporsi E, Chinet-Charrot P, Coudert B, Couette JE, Guastalla JP, Lebrun D, Ispas S, Blumberg J. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French Anticancer Federation study. Gynecol Oncol 1999; 75:187–193.
47. Pustilnik T, Burke TW. Adjuvant chemotherapy for high-risk endometrial cancer. Semin Radiat Oncol 2000; 10(1):23–28.
48. Muss HB, Blessing JA, DuBeshter B. Echinomycin in recurrent metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16(6):492–493.
49. Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. Am J Clin Oncol 1993; 16(1):18–21.
50. Randall ME, Spirtos NM, Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (Phase III): Gynecologic Oncology Group study no. 122. Monogr Natl Cancer Inst 1995; 19:13–15.